Skip to content
DataLookout
Menu

NCT07532655

A Single Ascending Dose and Multiple Ascending Doses Study of SYH2082 Injection in Healthy Participants

StatusRecruiting
PhasePhase 1
Primary completion (estimated)

At risk: Primary completion moved at least 3 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Recruitment opened Show 8 more changesShow less
    • Eligibility criteria expanded, about 198 words
    • Primary completion pushed from Oct 28, 2026 to Jan 30, 2027
    • Enrollment increased: 44 → 60 participants
    • Study completion pushed from Feb 9, 2027 to May 9, 2027
    • Study sites: 0 to 1
    • Start date changed from estimate of Apr 14, 2026 to Apr 10, 2026
    • Secondary endpoints: details revised at 15 of 15 entries
    • Study title expanded, about 4 words
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Number of Adverse Events as a measure of safety and tolerability of SYH2082
Timeframe: SAD: Screening period up to day 57 MAD: Screening period up to day 85

Secondary (15)

Maximum plasma concentration (Cmax)
Area under the concentration-time curve from time 0 to the last measurable time point (AUClast)
Area under the concentration time curve from time 0 to infinity (AUCinf)
Time to maximum concentration (Tmax)
Elimination half-life (t1/2)
Show 10 moreShow less
Apparent volume of distribution (Vz/F)
Apparent clearance (CL/F)
Anti-SYH2082 antibodies
Change in fasting plasma glucose from baseline
Change in fasting insulin from baseline
Change in C-peptide from baseline
Change in glucagon from baseline
Change in body weight from baseline
Change in waist circumference from baseline
Corrected QT(QTc) interval

Arms and interventions

SYH2082 InjectionExperimental

Single-ascending dose and multiple-dose doses

PlaceboPlacebo comparator

Conduct in accordance with the study protocol.

Drugs: SYH2082 Injection, Placebo

Sites

1 site in 1 country

  • Linear Clinical ResearchNedlands, Western Australia, Australia